Patents Assigned to Inscripta, Inc.
  • Patent number: 11566241
    Abstract: Disclosed systems and methods relate to predicting the relative representation of genomic variants in an edited cell population, based on the editing cassette design representation in an editing cassette design library used to generate the edited cell population. A library of editing cassette designs is generated, and a feature vector, or sequence embedding, is developed for each design using natural language processing techniques. The feature vector may be based upon sequence attributes and editing kinetics of each cassette design as well as attributes that describe the library context. Features may include sequence embeddings generated from a neural network, linguistic-type distances, and statistical distance summaries thereof. The feature vectors are classified using one or more machine learning models, and the classified feature vectors are used to predict the representation of each design an edited cell population.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: January 31, 2023
    Assignee: Inscripta, Inc.
    Inventors: Andrea Halweg-Edwards, Thomas Hraha, Krishna Yerramsetty, Shea Lambert, Miles Gander, Matthew David Estes, Chad Douglas Sanada, Isaac David Wagner, Paul Hardenbol
  • Patent number: 11555184
    Abstract: The present disclosure methods for identifying binding partners using cell surface display libraries, where the cells of the library display engineered peptides on their cell surfaces for identification of peptides that bind to targets of interest. The engineered peptides are preferably expressed in the cells under conditions that provide both secretion and display of the engineered peptides on the cell surfaces, thus providing access of the engineered peptides to identify potential binding pairs. The cell libraries cab be engineered using an automated editing system that provides for one or more targeted edits per cell.
    Type: Grant
    Filed: August 9, 2020
    Date of Patent: January 17, 2023
    Assignee: Inscripta, Inc.
    Inventors: Stephen Federowicz, Deanna Church, Michael Graige
  • Patent number: 11542633
    Abstract: The present disclosure provides shuttle vectors for editing exogenous polynucleotides in heterologous live cells, as well as automated methods, modules, and multi-module cell editing instruments and systems for performing the editing methods.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: January 3, 2023
    Assignee: Inscripta, Inc.
    Inventors: Richard Fox, Daniel Held
  • Patent number: 11512297
    Abstract: The present disclosure provides compositions and methods to increase the percentage of edited cells in a cell population when employing nucleic-acid guided editing, as well as automated multi-module instruments for performing these methods. Specifically, the disclosure relates to methods, compositions, modules and automated multi-module cell processing instruments that increase the efficiency of nucleic acid-guided editing in a cell population using a nucleic acid nuclease (i.e., an RNA-guided nuclease or “RGN”)/single-strand binding protein (“SSB”) fusion system. The system leverages a single-strand binding protein (SSP) and single-strand DNA annealing protein (“SSAP”) interactions to drive enhanced recruitment.
    Type: Grant
    Filed: November 9, 2021
    Date of Patent: November 29, 2022
    Assignee: Inscripta, Inc.
    Inventors: Andrew Garst, Tian Tian, Daniel Held
  • Patent number: 11473214
    Abstract: The present disclosure provides instrumentation and automated methods for creating cell surface display libraries, where the cells of the library display engineered peptides on their cell surfaces for identification of antigens that bind to T-cell receptors. The engineered peptides may be putative antigens or binding regions of the T-cell receptors.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: October 18, 2022
    Assignee: Inscripta, Inc.
    Inventors: Stephen Federowicz, Deanna Church, Michael Graige
  • Patent number: 11408012
    Abstract: Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods.
    Type: Grant
    Filed: January 29, 2022
    Date of Patent: August 9, 2022
    Assignee: Inscripta, Inc.
    Inventors: Andrew Garst, Ryan T. Gill, Tanya Elizabeth Warnecke Lipscomb
  • Patent number: 11407994
    Abstract: This invention relates to compositions of matter, methods, modules and instruments for automated mammalian cell growth and mammalian cell transduction followed by nucleic acid-guided nuclease editing in live mammalian cells. The present compositions and methods entail viral delivery of an editing cassette to live mammalian cells such that the editing cassettes edit the cells and the edited cells continue to grow, preferably using a fully-automated end-to-end instrument to process the cells without human intervention to enhance cell processing uniformity and to maintain the integrity of the cell culture.
    Type: Grant
    Filed: January 25, 2022
    Date of Patent: August 9, 2022
    Assignee: Inscripta, Inc.
    Inventors: Phillip Belgrader, Christian Siltanen, William Watterson, Burak Dura, Bruce Chabansky, David Stumbo, Eric Smith, Jorge Bernate
  • Patent number: 11396718
    Abstract: The present disclosure provides instrumentation and automated methods for creating cell surface display libraries, where the cells of the library display engineered peptides on their cell surfaces for identification of antigens that bind to T-cell receptors. The engineered peptides may be putative antigens or binding regions of the T-cell receptors.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: July 26, 2022
    Assignee: Inscripta, Inc.
    Inventors: Stephen Federowicz, Deanna Church, Michael Graige
  • Patent number: 11365383
    Abstract: The present disclosure provides automated modules and instruments for improved detection of nuclease genome editing of live cells. The disclosure provides improved modules—including high throughput modules—for screening cells that have been subjected to editing and identifying and selecting cells that have been properly edited.
    Type: Grant
    Filed: February 21, 2022
    Date of Patent: June 21, 2022
    Assignee: Inscripta, Inc.
    Inventors: Eileen Spindler, Amy Hiddessen, Andrew Garst, Michael Graige, Richard Fox, Phillip Belgrader, Don Masquelier, Bruce Chabansky
  • Patent number: 11359187
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Grant
    Filed: February 24, 2022
    Date of Patent: June 14, 2022
    Assignee: Inscripta, Inc.
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
  • Patent number: 11345903
    Abstract: The present disclosure provides engineered RNA-guided enzymes for editing live cells.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: May 31, 2022
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Kyle Seamon, Andrew Garst
  • Patent number: 11332850
    Abstract: The present disclosure provides shuttle vectors for editing exogenous polynucleotides in heterologous live cells, as well as automated methods, modules, and multi-module cell editing instruments and systems for performing the editing methods.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: May 17, 2022
    Assignee: Inscripta, Inc.
    Inventors: Richard Fox, Daniel Held
  • Patent number: 11332742
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells; specifically, the present disclosure provides Type V MAD nucleases (e.g., RNA-guided nucleases or RGNs) with altered PAM preferences and/or altered activity at different temperatures or fidelity, and/or varied nuclease activities; all changes that may increase the versatility of a nucleic acid-guided nuclease for certain editing tasks.
    Type: Grant
    Filed: January 3, 2022
    Date of Patent: May 17, 2022
    Assignee: Inscripta, Inc.
    Inventors: Juhan Kim, Benjamin Mijts, Aamir Mir
  • Patent number: 11319542
    Abstract: The present disclosure relates to methods for increasing observed editing rates in the surviving bacteria cells. The compositions and methods presented herein in combination lead to a phenomenon of “edit or die.” Although less cells survive plating and editing, a large percentage of cells that do survive are multiple editors. In one experiment it was found that if a cell survives transformation, plating, and editing, 75% of the surviving cells are multiple editors; that is, 75% of the surviving cells were simultaneously edited with edits at two or more different locations within the bacterial genome.
    Type: Grant
    Filed: November 28, 2021
    Date of Patent: May 3, 2022
    Assignee: Inscripta, Inc.
    Inventors: Tian Tian, Eileen Spindler, Charles Johnson, Clint Davis
  • Patent number: 11306299
    Abstract: The present disclosure provides compositions of matter, methods and instruments for editing nucleic acids in live yeast cells.
    Type: Grant
    Filed: November 3, 2021
    Date of Patent: April 19, 2022
    Assignee: Inscripta, Inc.
    Inventors: Skylar Stefani, Tian Tian, Miles Gander
  • Patent number: 11306327
    Abstract: Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: April 19, 2022
    Assignee: Inscripta, Inc.
    Inventors: Andrew Garst, Ryan T. Gill, Tanya Elizabeth Warnecke Lipscomb
  • Patent number: 11306298
    Abstract: The present disclosure provides new RNA-guided nuclease systems and engineered nickases for making rational, direct edits to nucleic acids in live cells.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: April 19, 2022
    Assignee: Inscripta, Inc.
    Inventors: Juhan Kim, Benjamin Mijts, Aamir Mir
  • Patent number: 11299731
    Abstract: The present disclosure relates to compositions, methods, modules and automated integrated instrumentation for multiplex delivery of “landing pad” edits into the genomes of a population of live cells. The landing pads then may be leveraged to insert very large DNA sequences into the genomes of the population of live cells.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: April 12, 2022
    Assignee: Inscripta, Inc.
    Inventor: Daniel Held
  • Patent number: 11293117
    Abstract: The present disclosure provides instrumentation and automated methods for creating cell surface display libraries, where the cells of the library display engineered peptides on their cell surfaces for identification of antigens that bind to T-cell receptors. The engineered peptides may be putative antigens or binding regions of the T-cell receptors.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: April 5, 2022
    Assignee: Inscripta, Inc.
    Inventors: Stephen Federowicz, Deanna Church, Michael Graige
  • Patent number: 11293021
    Abstract: In an illustrative embodiment, automated multi-module cell editing instruments are provided to automate multiple edits into nucleic acid sequences inside one or more cells.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: April 5, 2022
    Assignee: Inscripta, Inc.
    Inventors: Jorge Bernate, Kevin Ness, Phillip Belgrader, Don Masquelier, Ryan Gill